True—provided that the virus doesn't quickly become resistant to the drug.
I'm not saying ReViral's RSV fusion inhibitor won't work well, but rather that its MoA leaves a smaller margin for error than an N-protein inhibitor such as ENTA's, and it's more likely (IMO) that it would need to used in a combination regimen.
There may also be differences in safety/tolerability to distinguish the various RSV drugs in development.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.